Xeltis Raises €50 Million to Advance Commercialization of aXess Vascular Access Conduit

Netherlands-based Xeltis has obtained nearly €50 million in new financing to accelerate commercialization of aXess, its vascular access conduit designed for patients undergoing hemodialysis. The funding includes up to €37.5 million from the European Investment Bank (EIB), supported by the European Commission’s InvestEU program, and €10 million from existing shareholders such as EQT Life Sciences and Invest-NL. The company plans to use the capital to scale manufacturing, expand its workforce, and support development across its broader implant portfolio.

The investment follows strong results from Xeltis’ EU pivotal trial, which assessed the patency, safety, and performance of aXess in adults with end-stage renal disease requiring vascular access. The device met all primary endpoints and demonstrated sustained patency along with reduced infections and fewer interventions compared with current standards of care. A US pivotal trial is progressing, with interim data expected in 2026 ahead of a planned pre-market approval submission.

With this new funding, Xeltis expects to move aXess closer to both European market approval and US pre-market approval in 2026. “We are deeply grateful for the continued support of the EIB and our existing investors and proud of the confidence they have shown in Xeltis at this key moment for the company,” said CEO Eliane Schutte. She noted that the company is preparing to expand its facilities and hire additional staff to bring aXess to market.

Robert de Groot, Vice President at the EIB, said the bank is backing the project because “Xeltis is at the cutting-edge of their field, directly contributing to improved outcomes for dialysis and cardiovascular patients.” He emphasized that the €37.5 million venture debt commitment reflects Europe’s aim to strengthen its MedTech leadership.

Xeltis will also channel part of the financing toward its pipeline of implants developed using its Endogenous Tissue Restoration platform. This includes Xabg, a coronary artery bypass conduit that recently delivered strong 24-month follow-up results, and several other early-stage programs targeting additional cardiovascular conditions.